axitinib + cisplatin + capecitabine

**Axitinib + cisplatin + capecitabine** is a combination regimen of three drugs studied in clinical trials for the treatment of advanced solid tumors, most notably advanced gastric cancer. - **Axitinib** is a potent, selective, oral second-generation small molecule inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1/2/3), blocking VEGF-mediated signaling to inhibit angiogenesis and tumor growth[1][2][3]. - **Cisplatin** is a platinum-based small molecule cytotoxic chemotherapy that forms DNA cross-links, leading to apoptosis and cell death. - **Capecitabine** is an oral small molecule chemotherapeutic prodrug that is converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and interferes with DNA synthesis. This combination was evaluated in phase I studies, with axitinib administered at 5 mg twice daily alongside therapeutic doses of cisplatin and capecitabine. The regimen aims to combine anti-angiogenic targeted therapy with cytotoxic chemotherapy for synergistic antitumor effects[1][3]. Its primary indications studied include advanced gastric cancer and other solid tumors.

Brand names

InlytaPlatinolXeloda

Other names

Axitinib plus Cisplatin and CapecitabineAXI + XP